Absci Reports Q1 Revenue of $0.2M, R&D Expenses of $19.3M
Reports Q1 revenue $0.2M, consensus $1.41M. Reports Q1 research and development expenses increased to $19.3M, primarily driven by the advancement of internal programs, including direct costs associated with external preclinical and clinical development of ABS-201. "2026 is going to be a data-rich year for Absci with multiple readouts ahead," said CEO Sean McClain.
